Watson Pharmaceuticals Announces New Research Showing RAPAFLO Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Watson Pharmaceuticals WPI Announces New Research Showing RAPAFLO Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome New data presented today show that RAPAFLO significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome.  In the study presented at the annual meeting of the American Urological Association, RAPAFLO also significantly improved urinary symptoms as well as quality of life. Chronic prostatitis/chronic pelvic pain syndrome is a common condition characterized by persistent discomfort in the lower pelvic area and can have significant impact on quality of life. Symptoms can be severe and include painful and frequent urination and difficult or painful ejaculation. By definition, this type of prostatitis is not associated with a bacterial infection, and the cause is unknown. As many as 10 percent of men in North America have had or will have experienced prostatitis symptoms, and 90 percent of them have CP/CPPS. Evaluated in this trial for CP/CPPS, RAPAFLO is a uniquely selective alpha blocker approved for the treatment of the signs and symptoms of benign prostatic hyperplasia, commonly referred to as an enlarged prostate.